

**Press release (26.09.2019)**

**Council of Scientific and Industrial Research**

**Cadila Healthcare Limited**

**Wins**

**CSIR Diamond Jubilee Technology Award (CDJTA)-2017**

CSIR Diamond Jubilee Technology Award for the year 2017 is conferred on Cadila Healthcare Limited for developing 'Saroglitazar'- World's first approved drug for treating diabetic dyslipidemia and India's first indigenously discovered and developed New Chemical Entity (NCE) from a Pharmaceutical Company.

Cadila has designed this novel molecule that binds and interacts with the specific subtypes of Peroxisome Proliferator-Activated Receptors (PPARs) in a unique manner and addresses two major lifestyle diseases - diabetes and dyslipidemia by this one drug alone. Discovery of saroglitazar is a paradigm shift that included use of classical as well as state-of-the-art technology platforms while following global quality standards and using cost-efficient and home grown models/strategies.

The unique molecular mechanism of the drug has caught the interest of many multinational companies and also put India on the world map of countries that have discovered their own NCEs. With this innovation, Cadila has also established a new trend of discovering and developing the drug entirely within the country and making them available to Indian patients. More than a million patients with diabetic dyslipidemia in India have been treated with saroglitazar.

CSIR applauds and honors Cadila Healthcare Limited for this significant innovation, which has underscored the technological prowess of the country.